Login to Your Account



Other News To Note


Monday, December 17, 2012

• Ligand Pharmaceuticals Inc., of San Diego, and Pfizer Inc., of New York, said the FDA accepted for review a new drug application for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, as well as the prevention of postmenopausal osteoporosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription